About Upexi, Inc
- Industry: Consumer products
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://ir.upexi.com
Frequently Asked Questions
What is the 52-week range for UPXI?
The 52-week high is $7.75 and the 52-week low is $0.54.
What is the P/E ratio for UPXI?
The P/E ratio data is currently unavailable.
What is the dividend yield for UPXI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -139.91%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -984.34%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.26.
Analyst Recommendation Trends
Wall Street analyst consensus for UPXI over the last few months:
Latest UPXI News
Upexi (UPXI) Q4 2026 Earnings Call Transcript
Solana treasury strategy generated $17.4M in staking revenue despite market headwinds.
Upexi, Inc. Q4 2026 Earnings Call Summary
Moby summary of Upexi, Inc.'s Q4 2026 earnings call
Cantor Fitzgerald Reiterates Overweight on Upexi, Maintains $2 Price Target
Cantor Fitzgerald analyst Gareth Gacetta reiterates Upexi (NASDAQ:UPXI) with a Overweight and maintains $2 price target.
Upexi Inc (UPXI) (Q4 2026) Earnings Call Highlights: Massive Solana Treasury Fuels $246 Million ...
Upexi Inc (UPXI) slashed debt and cut staff to 10 while holding 2.34 million Solana tokens, but unrealized crypto losses drove a staggering fiscal 2026 net loss.
Upexi, Inc. (UPXI) Q4 2026 Earnings Call Transcript
Upexi, Inc. (UPXI) Q4 2026 Earnings Call September 17, 2026 5:30 PM EDTCompany ParticipantsAllan Marshall - CEO, President & Chairman of the BoardBrian...
Upexi Q4 Earnings Call Highlights
Upexi (NASDAQ:UPXI) said it strengthened its balance sheet, reduced operating expenses and continued to build its Solana treasury during fiscal 2026, though declines in digital-asset values drove a substantially wider full-year net loss. The company’s fiscal fourth quarter ended June 30, 2026, mark
Full Transcript: Upexi Q4 2026 Earnings Call
Upexi (NASDAQ:UPXI) released fourth-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
Upexi Q4 EPS $(0.21) Misses $(0.12) Estimate, Sales $3.149M Miss $7.572M Estimate
Upexi (NASDAQ:UPXI) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.12) by 75 percent. This is a 16 percent increase over losses of $(0.25) per share from the same
Earnings Scheduled For September 17, 2026
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on revenue of $9.10
Dow Tumbles Over 600 Points as Fed Raises Rates: Investor Sentiment Weakens, Greed Index Remains in ‘Fear’ Zone
Market fear deepened as CNN’s index fell to 26; stocks mostly declined after the Fed’s rate hike, with the Dow dropping 631 points.
Fluence Energy, Lennar and 3 Stocks to Watch Heading Into Thursday
Stocks in focus: Generac surged 32.5% on Amazon deal; Fluence fell 15.9% on weak guidance; Lennar missed estimates and dropped 2.1%.
Cantor Fitzgerald Maintains Overweight on Upexi, Raises Price Target to $2
Cantor Fitzgerald analyst Gareth Gacetta maintains Upexi (NASDAQ:UPXI) with a Overweight and raises the price target from $1.3 to $2.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-03 | Dugan Lawrence | +100,000 | - | - |
| 2026-07-03 | Rudick Brian Benjamin | +400,000 | - | - |
| 2026-07-03 | Salkind Gene | +100,000 | - | - |
| 2026-07-03 | Norstrud Andrew James | +400,000 | - | - |
| 2026-07-03 | MARSHALL ALLAN | +2,000,000 | - | - |
| 2025-12-23 | MARSHALL ALLAN | +50,000 | $1.8 | $90,000 |
| 2025-12-16 | MARSHALL ALLAN | +50,000 | $2.07 | $103,500 |
| 2025-12-15 | MARSHALL ALLAN | +100,000 | $2.07 | $207,000 |
| 2025-11-20 | Salkind Gene | +50,000 | $2.55 | $127,500 |
| 2025-11-17 | Salkind Gene | +100,000 | $2.81 | $281,000 |
| 2025-11-17 | Salkind Gene | +100,000 | $2.65 | $265,000 |